Floatz logo

L-Dep

PD-1 Antibody

Beijing Friendship HospitalPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the PD-1 Antibody cohort.

Asset / SponsorPhaseRating
Tislelizumab
Sun Yat-sen University
Phase 2B
Carboplatin
Sun Yat-sen University
Phase 2B
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 2CCC
Herincar-Pd1 Cells
Ningbo Cancer Hospital
Phase 1/2CCC

Same molecule, other indications

L-Dep is also rated in:

hemophagocytic syndromeDormant
B
Indicative ·
60 / 100
View asset →
Epstein-Barr virus infectionDormant
B
Indicative ·
60 / 100
View asset →
Safety and EfficacyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →